Omeprazole Sodium for Injection

1. This product is a proton pump inhibitor of gastric parietal cells. It can specifically inhibit the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, thereby effectively inhibiting the secretion of gastric acid. Since H, K-ATPase is the last process of acid secretion of parietal cells, this product has a strong acid inhibition ability. It can not only non-competitively inhibit gastric acid secretion caused by gastrin, histamine, choline, food, and stimulation of the vagus nerve, but also inhibit part of the basic gastric acid secretion that is not affected by choline or H2 receptor blockers. It also has a strong and lasting inhibitory effect on gastric acid secretion caused by dibutyl cyclic adenosine monophosphate (DCAMP) stimulation that cannot be inhibited by H2 receptor antagonists. 2. This product also has an inhibitory effect on pepsin secretion, and has no obvious change in gastric mucosal blood flow, nor does it affect body temperature, gastric cavity temperature, arterial blood pressure, venous hemoglobin, arterial oxygen partial pressure, carbon dioxide partial pressure and arterial blood pH.

Omeprazole sodium.

As an alternative treatment for the following conditions when oral therapy is not appropriate: duodenal ulcer, gastric ulcer, reflux esophagitis and Zollinger-Ellison syndrome.

1. Intravenous drip. 2. Dissolve the contents of the bottle in 100 ml of 0.9% sodium chloride injection or 100 ml of 5% glucose injection before use. After the product is dissolved, the intravenous drip time should be 20-30 minutes or longer. 3. When oral therapy is not suitable for patients with duodenal ulcer, gastric ulcer and reflux esophagitis, the recommended intravenous drip dose of this product is 40 mg, once a day. 4. For patients with Zollinger-Ellison syndrome, intravenous drip of omeprazole sodium 60 mg is recommended as the starting dose, once a day. The daily dose may require a higher dose, and the dose should be individualized. When the daily dose exceeds 60 mg, it should be administered in two doses.

1. Omeprazole is well tolerated, and most adverse reactions are mild and reversible. The following adverse reactions were reported in clinical trials or routine use, but in many cases the causal relationship with omeprazole treatment itself has not been determined. Among the following adverse reactions: 2. Common refers to an incidence of ge; 1/100; uncommon refers to an incidence of ge; 1/1000, but 1/100; rare refers to an incidence of 1/10000. Common: Central and peripheral nervous system: headache. Digestive system: diarrhea, constipation, abdominal pain, nausea/vomiting and flatulence. Uncommon: Central and peripheral nervous system: dizziness, paresthesia, drowsiness, insomnia and vertigo. Liver: elevated liver enzymes. Skin: rash and (or) itching, urticaria. Others: discomfort. Rare: Central and peripheral nervous system: reversible mental confusion, agitation, aggressive behavior, depression and hallucinations, more common in critically ill patients. Endocrine system: gynecomastia in men. Digestive system: dry mouth, stomatitis and candidal infections of the gastrointestinal tract. Blood system: leukopenia, thrombocytopenia, agranulocytosis and various blood cell reductions. Liver: encephalopathy (seen in patients with previous severe liver disease), hepatitis or icteric hepatitis, liver failure. Muscle and bone; arthralgia, weakness and myalgia. Skin: photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), alopecia; Others: allergic reactions, such as angioedema, fever, bronchospasm, interstitial nephritis and anaphylactic shock. Increased sweating, peripheral edema, blurred vision, taste disturbances and hyponatremia. In other cases, irreversible visual impairment has occurred in severe patients who received intravenous omeprazole, especially at high doses, but there is no causal relationship.

It is contraindicated for those who are allergic to this product.

Precautions for children: There is no experience of using this product for children. Precautions for pregnancy and lactation: Although animal experiments have not found that this product has adverse effects on pregnancy and lactation or toxic or teratogenic effects on the fetus, it is recommended that pregnant and lactating women should avoid using it as much as possible. Precautions for the elderly: No dosage adjustment is required for elderly patients.

Because this product can reduce gastric acidity, the absorption of some drugs may be changed. Therefore, the absorption of ketoconazole and itraconazole will be reduced when treated with omeprazole or other acid inhibitors or antacids. Omeprazole is metabolized in the liver by cytochrome P4502C19 (CYP2C19), which will prolong the clearance of other enzymatic products such as diazepam, warfarin (R warfarin) and phenytoin. This product should be monitored when used in combination with warfarin and phenytoin, and the dose of warfarin or phenytoin should be reduced if necessary. Patients who continue to use phenytoin are given 20 mg of this product once a day, and the blood concentration of phenytoin is not affected. Similarly, patients who continue to use warfarin are given 20 mg of this product once a day, and the clotting time is not changed. When omeprazole is used in combination with clarithromycin, their blood concentrations will increase. However, there is no interaction when used in combination with metronidazole or amoxicillin. These antibiotics combined with omeprazole can eradicate H. pylori.

Keep tightly closed in a cool, dark place.

40mg (based on C17H19N3O3S)

24 months

Hubei Changlian Dule Pharmaceutical Co., Ltd.

• Founded in:

  2000-04-24

• Address:

  No. 180, Yixing Avenue, Yiling District, Yichang City, Hubei Province

• Tax NO.:

  914205066764994030

• Registered Funds:

  73.460277 yuan

• Email:

  Log in to view